Shares have done a lot of emotional whiplash this year: up 57.9% over 12 months, down 15.8% in six, and last seen at $18.60 (+1.7% on 2026-07-30).
The core fact is simple and large: Alignment Healthcare is getting much bigger and slightly more profitable. Revenue reached 3.9B in the latest fiscal year, a 46.1% increase, and operating margin moved into positive territory at +0.4% while net margin registered -0.0%.
Long-form metrics reinforce the move. Management's latest annual results show operating margin improved by 4.1 percentage points and net margin improved by 4.7 percentage points versus the prior year — the math of scale is clearly in play.
At the same time the balance sheet shows: market cap 3.7B, enterprise value 3.4B and net CASH of 252.6M. The stock's EV/sales is 0.9x — well below peer levels (the filing lists a -52.9% gap versus peers), producing an EV/sales figure below peers on a headline basis.
But the cheapness and the progress aren't the whole story. Costs that come with growth are visible in the filing.
"The increase was primarily due to the amount and timing of our capital expenditures and the 33 associated depreciation relative to 2025." [Alignment Healthcare / 10-Q 2026-07-30]
Management is flagging that capital spending (and the resulting higher depreciation) pushed costs up in the most recent period. In plain terms: the company is investing in capacity now, which lifts measured costs before the benefits fully land.
"The increase in interest expense was mainly attributable to an increase in debt issuance cost amortization related to the Revolving Credit Facility that was entered into in February 2026." [Alignment Healthcare / 10-Q 2026-07-30]
The filing also calls out higher interest-related expense tied to a new revolving credit facility. So while the company shows net cash today, it has added debt-related costs that will show up on the income statement.
Other frictions: diluted shares rose 3.8% in the latest year, which modestly dilutes per-share progress, and management continues to cite macro forces as a background risk in its filings.
Those mixed dynamics are exactly why valuation scenarios for Alignment look wildly ranged in the company's own sensitivity table. The firm lays out three mechanical scenarios for the next two years: a bull path with revenue CAGR of +40.0% and an exit P/S of 2.4x, a base with revenue CAGR of +30.0% and an exit P/S of 0.9x, and a bear with revenue CAGR of +12.0% and an exit P/S of 0.6x.
The takeaway from that math is structural: most of the gap between the bull and bear outcomes comes from the exit multiple the market assigns, not from small differences in growth assumptions. In other words, the same operational progress can produce very different market values depending on the multiple — and the company’s own scenario table shows that spread is enormous.
So the tension is straightforward and factual: Alignment is scaling fast and just nudged operating profitability, with a net-cash position of 252.6M and a low EV/sales; at the same time, rising capex, higher interest expense, and modest share dilution are real headwinds, and the stock's value is highly sensitive to the multiple the market chooses to pay.
Figures and quotes from Alignment Healthcare filings.